| Demographic and clinical characteristics |
| Female sex, n (%) |
14 (42%) |
| Age (median years, IQR) |
36 (31-42) |
| Baseline BMI (median kg/m2, IQR) |
16.7 (15.4-17.6) |
| Week 12 BMI (median kg/m2, IQR) |
17.6 (16.5-19.0)a |
| Baseline CD4+ count (median cells/μl, IQR) |
224 (151-256) |
| Week 12 CD4+ count (median cells/μl, IQR) |
349 (275-426)a |
| Median serum, urine, and cardiovascular values pre-treatment and after 12 weeks of antiretroviral therapy, median (IQR) |
| Variable |
Recruitment |
Week 12 of ART |
| C-reactive protein (mg/l) |
18.3 (4.5-64.8) |
6.4 (3.8-19.7)a |
| TNF-α receptor 1 (ng/ml) |
1.3 (0.8-2.4) |
1.0 (0.6–1.3)a |
| Soluble CD163 (ng/ml) |
684 (511-1022) |
531 (376-1040) |
| Soluble CD14 (μg/ml) |
2.4 (2.1-2.7) |
2.5 (2.0-3.1) |
| Isoprostane-to-creatinine ratio |
0.02 (0.01-0.05) |
0.09 (0.05-0.24)a |
| Augmentation Index |
11.9 (1.0-30.0) |
19.0 (0.1-25.9) |
| Reactive Hyperemia Index |
0.6 (0.3-0.8) |
0.6 (0.4-0.7) |
| QTc (ms) |
434 (421-447) |
431 (417-446) |
| RMSSD (ms) |
26.4 (17.5-41.3) |
37.2 (19.2-71.6)a |
| Triangular Index |
6.8 (5.9-10.6) |
9.6 (6.1-14.5) |
| Low frequency variations (ms2) |
130.2 (85.0-151.9) |
112.9 (76.1-151.6) |
| High frequency variations (ms2) |
214.7 (154.7-260.8) |
232.6 (169.7-327.1) |
| Power Ratio |
0.6 (0.4-0.9) |
0.4 (0.3-0.9) |
| Systolic blood pressure (mm Hg) |
100 (93-110) |
110 (100-120)a |
| Diastolic blood pressure (mm Hg) |
60 (60-70) |
70 (60-70) |
| Heart rate (bpm) |
78 (71-89) |
68 (63-82) |
| Abbreviation: BMI: Body Mass Index; QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences; TNF-α: Tumor Necrosis Factor-α.
Reactive hyperemia index is natural log transformed
a: p<0.05 for change at 12 weeks |
